Laskawi, Raíner

[["dc.bibliographiccitation.issue","18"],["dc.bibliographiccitation.journal","Head & face medicine"],["dc.bibliographiccitation.lastpage","7"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Rohrbach, Saskia"],["dc.contributor.author","Junghans, Katharina"],["dc.contributor.author","Köhler, Sibylle"],["dc.contributor.author","Laskawi, Rainer"],["dc.date.accessioned","2010-12-16T13:58:05Z"],["dc.date.accessioned","2021-10-27T13:22:32Z"],["dc.date.available","2010-12-16T13:58:05Z"],["dc.date.available","2021-10-27T13:22:32Z"],["dc.date.issued","2009"],["dc.description.abstract","Background: Nasal hypersecretion due to idiopathic rhinitis can often not be treated sufficiently by conventional medication. Botulinum toxin A (BTA) has been injected into the nasal mucosa in patients with nasal hypersecretion with a reduction of rhinorrhea lasting for about 4 to 8 weeks. Since the nasal mucosa is well supplied with glands and vessels, the aim of this study was to find out if the distribution of BTA in the nasal mucosa and a reduction of nasal hypersecretion can also be reached by a minimally invasive application by sponges without an injection. Methods: Patients were randomly divided into two groups. The effect of BTA (group A, C, D) or saline as placebo (group B) was investigated in 20 patients with idiopathic rhinitis by applying it with a sponge soaked with BTA (40 units each nostril) or saline. Subgroups C and D contained these patients of group A and B who did not improve in symptoms one week after the original treatment (either BTA or saline) who then received the alternative medication. Changes of symptoms (rhinorrhea, nasal obstruction) were scored by the patients in a four point scale and counted (consumption of tissues, sneezing) in a diary. The patients were followed up weeks 1, 2, 4, 8 and 12. Results: There was a clear reduction of the amount of secretion in group A compared to group B, C and D. This did not correlate with the tissue consumption, which was comparably reduced in group A and B, but reduced less in group C and D. Sneezing was clearly reduced in group A but comparably unchanged in group B and C and increased in group D. Nasal congestion remained unchanged. Conclusion: In some patients with therapy-resistant idiopathic rhinitis BTA applied with a sponge is a long-lasting and minimal invasive therapy to reduce nasal hypersecretion."],["dc.identifier.doi","10.1186/1746-160X-5-18"],["dc.identifier.pmid","19835591"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5811"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92104"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.issn","1746-160X"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.subject.mesh","Administration, Intranasal"],["dc.subject.mesh","Adult"],["dc.subject.mesh","Aged"],["dc.subject.mesh","Aged, 80 and over"],["dc.subject.mesh","Botulinum Toxins, Type A"],["dc.subject.mesh","Female"],["dc.subject.mesh","Humans"],["dc.subject.mesh","Male"],["dc.subject.mesh","Middle Aged"],["dc.subject.mesh","Neuromuscular Agents"],["dc.subject.mesh","Placebos"],["dc.subject.mesh","Rhinitis"],["dc.subject.mesh","Treatment Outcome"],["dc.title","Minimally invasive application of botulinum toxin A in patients with idiopathic rhinitis."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","44"],["dc.bibliographiccitation.journal","Head & Face Medicine"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Karapantzou, Chrisanthi"],["dc.contributor.author","Dressler, Dirk"],["dc.contributor.author","Rohrbach, Saskia"],["dc.contributor.author","Laskawi, Rainer"],["dc.date.accessioned","2018-11-07T09:33:27Z"],["dc.date.available","2018-11-07T09:33:27Z"],["dc.date.issued","2014"],["dc.description.abstract","Introduction: We describe the results of 15 patients suffering from essential blepharospasm with apraxia of eyelid opening who underwent frontalis suspension surgery. Material and methods: Patients with apraxia of eyelid opening and unresponsive to botulinum toxin injections were studied. Bilateral frontalis suspension surgery was performed (sling operation) using polytetrafluoroethylene (Gore-Tex (R)) sutures. The patients reported the degree of improvement using a subjective rating scale to evaluate the benefit of the operation at two times after surgery (0-10 days and 180-360 days). Results: The patients reported a high degree of subjective improvement. In the early postoperative period (0-10 days) the mean degree of subjective improvement was 74.6% (standard deviation (SD) 26.4%). At 180-360 days after surgery the mean improvement was 70.0% (SD 26.7%). Small hematomas of the upper lid occurred postoperatively in all patients. Other complications were suture extrusions (9.1%), suture granulomas (6.1%), lacrimation (5.0%) and local infections (7.5%). Postoperatively, all patients needed additional botulinum toxin injections for optimal outcome. Conclusion: Frontalis suspension surgery is a minimally invasive and effective treatment option for apraxia of eyelid opening in patients with essential blepharospasm unresponsive to botulinum toxin injections alone."],["dc.identifier.doi","10.1186/1746-160X-10-44"],["dc.identifier.isi","000344708200001"],["dc.identifier.pmid","25338619"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11008"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31967"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1746-160X"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Frontalis suspension surgery to treat patients with essential blepharospasm and apraxia of eyelid opening-technique and results"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Head & Face Medicine"],["dc.bibliographiccitation.lastpage","5"],["dc.bibliographiccitation.volume","3"],["dc.contributor.author","Junghans, Katharina"],["dc.contributor.author","Rohrbach, Saskia"],["dc.contributor.author","Ellies, Maik"],["dc.contributor.author","Laskawi, Rainer"],["dc.date.accessioned","2021-06-01T10:48:01Z"],["dc.date.available","2021-06-01T10:48:01Z"],["dc.date.issued","2007"],["dc.description.abstract","Background: Facial pain syndromes can be very heterogeneous and need individual diagnosis and treatment. This report describes an interesting case of facial pain associated with eczema and an isolated dyskinesia of the lower facial muscles following dental surgery. Different aspects of the pain, spasms and the eczema will be discussed."],["dc.description.abstract","Case presentation: In this patient, persistent intense pain arose in the lower part of her face following a dental operation. The patient also exhibited dyskinesia of her caudal mimic musculature that was triggered by specific movements. Several attempts at therapy had been unsuccessful. We performed local injections of botulinum toxin type A (BTX-A) into the affected region of the patient's face. Pain relief was immediate following each set of botulinum toxin injections. The follow up time amounts 62 weeks."],["dc.description.abstract","Conclusion: Botulinum toxin type A (BTX-A) can be a safe and effective therapy for certain forms of facial pain syndromes."],["dc.identifier.doi","10.1186/1746-160X-3-32"],["dc.identifier.fs","201926"],["dc.identifier.ppn","559812132"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/4369"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85799"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1746-160X"],["dc.relation.issn","1746-160X"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","616"],["dc.title","Improvement of chronic facial pain and facial dyskinesia with the help of botulinum toxin application"],["dc.title.alternative","Case report"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]